Health Care Reform and Possible Effects on Innovative Therapies: Cancer as a Case Study : Hearing Before the Subcommittee on Technology, Environment, and Aviation of the Committee on Science, Space, and Technology, U.S. House of Representatives, One Hundred Third Congress, Second Session, February 2, 1994, Volume 4U.S. Government Printing Office, 1994 - 198 pages |
Other editions - View all
Common terms and phrases
administration Administration's antibody areas biotech biotech companies biotech firms biotechnology companies biotechnology industry Biotechnology Industry Organization bone marrow transplant breakthrough drugs breast cancer cancer patients cancer research capital Chairman chemotherapy clinical trials Clinton colon cancer colorectal cancer committee competition CONGRE CONGRESS THE LIBRARY Curd cures disease doctors drug companies drug costs drug prices Duke effective Federal FELDBAUM funding gene therapy Genentech global going GRESS THE LIBRARY health care costs health care reform health care system HOKE hospital human impact incidence increased innovation investment investors Japan Johnson KLEIN LIBRA LIBRARY OF CONGRESS medical device industry medicine million National Cancer Institute percent pharmaceutical industry prescription price controls Price Regulation proposed protein RARY receptor research and development RESS spending subcommittee surgery Thank therapeutic Tim Valentine TREATMENT OF COLORECTAL tumor United VALENTINE WAGNER-JOHNSON women
Popular passages
Page 76 - Never doubt that a small group of thoughtful committed citizens can change the world. Indeed it's the only thing that ever has.
Page 141 - Agency is to enhance the quality, appropriateness, and effectiveness of health care services, and access to such services, through the establishment of a broad base of scientific research and through the promotion of improvements in clinical practice (including the prevention of diseases and other health conditions) and in the organization, financing, and delivery of health care services.
Page 182 - X face a 92 percent probability of death. will there be a drug for my disease if the National Health Board has the power to control prices? And if it won't have the authority to set prices, why do we need to spend $ 2 billion on a new Federal bureaucracy? Our deficits prove that we can't pay for the bureaucracy we already have. The irony of this foolishness as shown in Figure 8 is that Pharmaceuticals account for only 8 percent of total health expenditures. If all drugs were free, it would barely...
Page 141 - Agency, as stated by law, is to enhance the quality, appropriateness, and effectiveness of health care services...
Page 179 - Research has played an important role in the evolution of our health care system. Many of us would not be alive today if it were not for the success of past research. However, medical research is now threatened by health care reform. As shown in Figure 1, health care RSD as a percent of health care costs peaked in 19B2 and has declined consistently since then.
Page 129 - Kaposi's sarcoma (KS) was examined with the use of data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute.
Page 17 - US Congress, Office of Technology Assessment, Pharmaceutical R&D: Costs, Risks and Rewards, OTA-H-522 (Washington, DC: US Government Printing Office, February 1993). "Peter Coy et al, "What's the Word in the Lab? Collaborate,- Business Week, (June 27, 1994), 78-103.
Page 183 - India. Capital is being redeployed to other, more profitable areas. There have also been massive layoffs at major drug companies. My fear is that we are seeing the future of health care research right now. Let this be an early warning sign to the Congress and to the White House. Closing He need health care reform and there are many things which Congress can do to improve the situation.
Page 183 - Lower market value* mean that the cost of capital is going up and less capital is available. ultimately, capital flows are reflected in research budgets as well as in prices . As I mentioned, I have been involved in several high tech ventures. Currently* "word on the street...
Page 5 - I thank all of you for being here, and I look forward to hearing your testimony. Thank you, Mr. Chairman.